The present invention relates to a cosmetic composition comprising a branch portion extract comprising at least approximately 50 wt % of polyphenols and less than approximately 10 wt % of terpenes, relative to the total weight of the extract, in a cosmetically acceptable medium. The invention also relates to the use of such a cosmetic composition for combatting the signs of skin ageing and/or for reinforcing the skin barrier.
The present invention relates to a sublingual composition comprising a part of branch extract, preferably from at least one resinous tree comprising at least about 50 % by weight of polyphenols and less than about 10 % by weight of terpenes, relative to the total weight of the extract. The present invention further relates to the non-therapeutic uses of such sublingual composition for improving the respiratory wellness, relieving joint pain and/or muscular pain and cramps and/or improving endurance, and improving libido and/or fertility.
A61K 36/15 - Pinaceae (Pine family), e.g. pine or cedar
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
4.
NEW DERIVATIVES OF CEPHALOSPORIN FOR TREATING CANCER
The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.
A61K 31/545 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
The present invention relates to a knot-wood extract comprising at least one lignan selected from the list comprising (-)-hydroxymatairesinol (two epimers; 7S, 8R, 8'R and 7R, 8R, 8'R), (-)(7S, 8R, 8'R)-hydroxymatairesinol, (+)-lariciresinol, (-)-secoisolariciresinol, liovil and any epimers thereof. The present invention also relates to a method of activating a β2 adrenergic receptor, comprising administering an effective amount of a knot-wood extract of the invention or of at least one lignan selected from the list comprising (-)-hydroxymatairesinol (two epimers; 7S, 8R, 8'R and 7R, 8R, 8'R), (-)(7S, 8R, 8'R)-hydroxymatairesinol, (+)-lariciresinol, (-)-secoisolariciresinol, liovil and any epimers thereof. The present invention also relates to a method of treating a β2 adrenergic receptor related disease in a subject in need thereof, comprising administering to the subject an effective amount of a knot- wood extract of the invention or of at least one lignan selected from the list comprising (-)-hydroxymatairesinol (two epimers; 7S, 8R, 8'R and 7R, 8R, 8'R), (-)(7S, 8R, 8'R)-hydroxymatairesinol, (+)-lariciresinol, (-)-secoisolariciresinol, liovil and any epimers thereof.
A61K 36/76 - Salicaceae (Willow family), e.g. poplar
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 36/15 - Pinaceae (Pine family), e.g. pine or cedar
The present invention relates to a compound for use in the prevention and/or treatment of a disease selected from a neurodegenerative disease, especially Alzheimer disease, and a disease, disorder or condition involving an activation of phosphodiesterase-4 (PDE4), wherein said compound is of general formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X and Z each independently represent CH or N; Y represents O or S; R1, R2 and R3 may be the same or different and represent a hydrogen atom, a halogen atom, hydroxyl, nitro, cyano, amino, amido, carbamate, alkyl, alkenyl, alkynyl, alkoxy, heterocyclic, carbocyclic, alkylthio, carboxy, or alkoxycarbonyl; R4 represent a hydrogen atom; R5, R6, R7 and R8 may be the same or different and represent a hydrogen atom, halogen atom, hydroxyl, nitro, amino, alkyl, alkoxy, alkylthio, or tnfluoromethyl; R9 and R10 may be the same or different and represent a hydrogen atom, alkyl, alkylcarbonyl, heterocyclic, carbocyclic, ON02, or OS02R wherein R is hydroxyl, alkyl, carbocyclic; and R11 represents an alkyl, alkenyl, alkynyl, alkoxy, akoxycarbonyl, amino, amido, heterocyclic, carbocyclic, or optionally substituted azolyl.
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
patents
